# Evaluation of Efficacy and Safety When Administered JP-2266 in Type 2 Diabetes Patients

Study · id `cardio:ct-nct06144788` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06144788](<https://clinicaltrials.gov/study/NCT06144788>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06144788

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 161 participants.

## Technical summary

Registry record NCT06144788. Randomized; triple masking; primary purpose treatment. Start 2023-11-03 (actual); primary completion 2024-12-23 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 161 participants (enrolled count; ClinicalTrials.gov record NCT06144788, source copy `cardio:ctgov-nct06144788-2026-07-07`, retrieved 2026-10-26)
- Started: 2023-11-03 (actual) (ClinicalTrials.gov record NCT06144788, source copy `cardio:ctgov-nct06144788-2026-07-07`, retrieved 2026-10-26)
- Primary completion: 2024-12-23 (actual) (ClinicalTrials.gov record NCT06144788, source copy `cardio:ctgov-nct06144788-2026-07-07`, retrieved 2026-10-26)
- Completion: 2024-12-23 (actual) (ClinicalTrials.gov record NCT06144788, source copy `cardio:ctgov-nct06144788-2026-07-07`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT06144788, source copy `cardio:ctgov-nct06144788-2026-07-07`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06144788-2026-07-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: Evaluation of Efficacy and Safety When Administered JP-2266 in Type 2 Diabetes Patients
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): SGLT2 inhibitor
- Lead sponsor: Jeil Pharmaceutical Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record once doses, forms and salt words are removed: SGLT2 inhibitors (drug class) (`cardio:sglt2-inhibitors`)
- Registry lists this organization as the lead sponsor: Jeil Pharmaceutical Co., Ltd. (`cardio:org-jeil-pharmaceutical-co-ltd`)

## Provenance

Content hash: 76e3c8b5ba8a32179191fa346a3eb06deb72704df8d79d71807e52ab6f68c442
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
